Citadel Advisors
SLXN

Citadel Advisors’s Silexion Therapeutics SLXN Stock Holding History

Citadel Advisors’s Portfolio SLXN Stock Details SLXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$26.8K Buy
2,093
+872
+71% +$15.3K ﹤0.01% 12607
2025
Q4 		$23.4K Buy
+1,221
New +$36.7K ﹤0.01% 12303

Other funds holding SLXN

TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
MA
Montag & Associates Atlanta, Georgia $2.37B AUM 28.86% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
PK
Pflug Koory Omaha, Nebraska $250M AUM 42.29% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Citadel Advisors's SLXN Position: Q1 2026 in Review

Citadel Advisors increased its Silexion Therapeutics (SLXN) stake by 71% in Q1 2026, buying an estimated $15.3K and bringing the position to 2,093 shares worth $26.8K. The position accounts for ﹤0.01% of the portfolio, ranked #12607.

Citadel Advisors first reported a position in SLXN in Q4 2025 and has held it in 2 quarters since. 7 funds tracked by Wall St. Rank hold SLXN as of Q1 2026.

  • Citadel Advisors held 2,093 shares of Silexion Therapeutics worth $26.8K as of Q1 2026.
  • Citadel Advisors bought 872 Silexion Therapeutics shares in Q1 2026, an estimated $15.3K.
  • Silexion Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #12607 holding.
  • Citadel Advisors first reported a position in Silexion Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 7 funds tracked by Wall St. Rank held Silexion Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.